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Background: To investigate clinical outcomes of percutaneous coronary intervention using a sirolimus-eluting
stent with bioresorbable polymer, Ultimaster (BP-SES) compared with a permanent polymer everolimus-
eluting stent, Xience (PP-EES) in patients with high risk (ST-segment elevation and non-ST-segment elevation
myocardial infarction) acute coronary syndromes (ACS) enrolled in the CENTURY II trial.
Methods: CENTURY II is a prospective, multicenter, randomized, single blind, controlled trial comparing BP-SES
and PP-EES, with primary endpoint of target lesion failure (TLF) at 9 month post-stent implantation. Out of
1123 patients enrolled in CENTURY II trial, 264 high risk ACS patients were included in this subgroup analysis,
and the clinical outcomes including target lesion failure (TLF), target vessel failure (TVF), cardiac death, myocar-
dial infarction, and stent thrombosis were evaluated at 24 months.
Results: The baseline clinical, angiographic and procedural characteristics were similar between two groups. At
24 months, TLF occurred in 6.3% of patients receiving a BP-SES and 6.5% of patients receiving a PP-EES (P =
0.95); TVF was 6.3% in patients receiving a BP-SES and 9.4% in patients receiving a PP-EES (P = 0.36). There
were no signiﬁcant differences in cardiac death, myocardial infarction and stent thrombosis rate.
Conclusions: BP-SES achieved similar safety and efﬁcacy outcomes as PP-EES in this ACS subgroup of CENTURY II study, at
24-month follow-up. Thisﬁnding is hypothesis-generating andneeds to be conﬁrmed in larger trialswith longer follow-up.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Late stent thrombosis (ST) and late stent restenosis have been asso-
ciated with a chronic inﬂammatory vessel response induced bygrants from Abbott Vascular and Ter
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drawbacks, providing safety and beneﬁts in different clinical settings,
including stable coronary artery disease (CAD) and acute coronary
syndromes (ACS).
The safety and effectiveness of BP-based DES over bare metal stents
[2] (BMS) andﬁrst-generationDES [3] has been proven previously in re-
ducing the risk of very late ST and restenosis [4]. Patients with ACS con-
stitute a challenging subset with poorer outcomes after percutaneous
coronary interventions (PCI) as compared to stable CAD, with an in-
creased risk of ST and reinfarction. Therefore, the potential beneﬁts of
a BP-based DES in patients with ACS are important, but its efﬁcacy and
safety remains to be conﬁrmed.
In the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting
Coronary Stent System in the Treatment of Patients with Coronary Ar-
tery Disease) trial, a sirolimus-eluting stent with BP, Ultimaster (BP-
SES) showed safety and efﬁcacy proﬁles similar to permanent polymer
everolimus-eluting stent (PP-EES) at 9-month follow-up [5].
To date, there are few data regarding the comparison of the current
gold-standard generation DES with the BP-SES in patients with high-
risk ACS, including ST-segment elevation myocardial infarction
(STEMI) and non-STEMI patients (NSTEMI). We present the analysis
of a subgroup of patients with high risk ACS treated with BP-SES or
PP-EES in the CENTURY II trial.2. Methods
2.1. Study design
The CENTURY II study design and study devices have been described
in detail in a previous publication [5]. In brief, CENTURY II is a prospec-
tive, multicenter, randomized (1:1), single blind, controlled, non-
inferiority, two-arm trial of BP-SES (Ultimaster DES, Terumo Corpora-
tion, Tokyo, Japan) and PP-EES (Xience DES, Abbott Vascular, Santa
Clara, California, USA). Patients aged ≥18 years, with clinical evidence
of ischemic heart disease and/or a positive functional study, good candi-
dates for PCI using DES and acceptable candidates for CABG with refer-
ence vessel diameter between ≥2.5 mm and ≤4.0 mmwere included in
the study. A complete description of exclusion criteria is listed in Sup-
plementary Appendix.
The global study included 1123 patients in 58 participating centers
from Europe, Japan, and Korea, from February 2012 to January 2013.
The current study included all patients with high-risk ACS (STEMI and
NSTEMI). This ACS subgroup was prespeciﬁed in the protocol. Except
for Japan (15 sites), and South Korea (1 site), all European centers (42
sites in 11 European countries) enrolled patients with high risk ACS
(complete list in supplementary appendix). The study was approved
by the institutional review committee at each participating center and
all patients provided written informed consent.Fig. 1. Flow chart of CENTURY II ACS substudy ITT= intention to treat; PP= per-protocol;
ACS = acute coronary syndromes; BP-SES = bioresorbable polymer sirolimus-eluting
stent; PP-EES= permanent polymer everolimus-eluting stent; STEMI= ST-segment ele-
vation myocardial; NSTEMI = non-ST segment elevation myocardial.2.2. Procedures
PCIwere performed according to standard hospital practice. Patients
were randomly assigned (1:1) to receive either BP-SES or PP-EES. Ran-
domization of patients was stratiﬁed by general inclusion and exclusion
criteria and balanced for diabetes mellitus, ACS (STEMI and NSTEMI)
and multivessel disease. All further procedures (lesion pre-dilation,
stenting or post-stenting dilation, usage of imagingmodalities for result
optimization or glycoprotein (GP) IIb/IIIa inhibitors) were left at
operator's discretion. Dual antiplatelet therapy (DAPT) prescription
was according to hospital practice in all patients, with a duration for at
least 6 months as per protocol recommendation. DAPT beyond
6 months was at the discretion of the treating physician considering
prevailing guidelines [6]. All patients were to be followed up at 1, 4,
and 9 months and yearly up to 5 years.2.3. Endpoints and deﬁnitions
The primary endpoint of CENTURY II study was target lesion failure
(TLF), a device-oriented composite endpoint (cardiac death, MI not
clearly attributable to a non-target vessel, and clinically driven target le-
sion revascularization [TLR]) at 9 months post-stent implantation. Sec-
ondary endpoints were: (i) rate of target vessel failure (TVF) deﬁned
as composite of cardiac death and MI not clearly attributable to a non-
target vessel, and clinically driven target vessel revascularization
(TVR); (ii) patient-oriented composite endpoint (POCE) composed of
all deaths, all MI and all coronary revascularizations; (iii) rate of TLR,
TVR, ST, cardiac death, and MI; (iv) composite of cardiac death and
MI; and (v) rate of bleeding and vascular complications according to
Bleeding Academic Research Consortium (BARC) deﬁnitions [7]. The
endpoints were deﬁned as per Academic Research Consortium (ARC)
recommendations [8].
2.4. Angiographic analysis
All angiograms were assessed by an independent core laboratory
(K.I.C. Co. Ltd, Kanagawa, Japan) using dedicated software (qAngio XA
ver. 7.1, Medis, the Netherlands). Main angiographic parameters at
Table 1
Baseline patient characteristics.
Total HR-ACS
n = 264
BP-SES
n = 126
PP-EES
n = 138
P value
Age, (years) 63.7 ± 11.3 63.1 ± 11.3 64.3 ± 11.4 0.45
Male gender, % (n) 82.2% (217) 79.3% (100) 84.7% (117) 0.25
Clinical presentation
STEMI, % (n) 23.1% (61) 23.0% (29) 23.1% (32) 0.97
NSTEMI, % (n) 76.8% (203) 76.9% (97) 76.8% (106) 0.97
Diabetes mellitus 23.4% (62) 25.4% (32) 21.7% (30) 0.48
Insulin-treated, % (n) 4.1% (11) 5.5% (7) 2.8% (4) 0.38
Hypertension, % (n) 58.0% (152) 58.8% (73) 57.2% (79) 0.79
Dyslipidemia, % (n) 51.9% (133) 48.3% (59) 55.2% (74) 0.27
Current smoking, % (n) 36.5% (95) 39.0% (48) 34.3% (47) 0.43
Previous MI, % (n) 33.3% (88) 31.7% (40) 34.7% (48) 0.60
Previous PCI, % (n) 21.5% (57) 21.4% (27) 21.7% (30) 0.95
Multivessel disease 50.3% (133) 47.6% (60) 52.9% (73) 0.39
LVEF, % 56.3 ± 11.3 55.7 ± 11.5 56.9 ± 11.1 0.63
Killip classiﬁcation 0.44
Class 1, % (n) 85.2% (52) 82.7% (24) 87.5% (28)
Class 2, % (n) 13.1% (8) 13.7% (4) 12.5% (4)
Class 3–4, % (n) 1.6% (1) 3.4% (1) 0.0% (0)
Complexity of CAD
≥1 lesion N20mm, % (n) 46.7% (123) 50.0% (63) 43.8% (60) 0.31
≥1 bifurcation, % (n) 12.5% (33) 11.9% (15) 13.0% (18) 0.78
Left main, % (n) 1.5% (4) 0.7% (1) 2.1% (3) 0.36
Total occlusion, % (n) 14.3% (38) 11.9% (15) 16.6% (23) 0.27
Syntax score 9.7 ± 6.5 9.2 ± 6.0 10.3 ± 6.9 0.25
Data are mean ± SD or %. HR-ACS: high risk acute coronary syndromes; BP-SES: biore-
sorbable polymer sirolimus-eluting stent (s); PP-EES: permanent polymer everolimus-
eluting stent(s); STEMI: ST-segment elevation myocardial infarction; NSTEMI: non-ST-
segment elevation myocardial infarction; CAD: coronary artery disease; MI: myocardial
infarction; PCI: percutaneous coronary intervention; LVEF, left ventricle ejection fraction.
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dure, percentage diameter stenosis (DS%), and acute gain (deﬁned as
the change in MLD from baseline to the ﬁnal procedural angiogram).Table 2
Baseline lesion and procedural characteristics.
Total HR-ACS
N = 264
Nlesion = 371
Number of stents implanted per patient, n 1.65 ± 0.90
Number of stents implanted per lesion, n 1.18 ± 0.44
Stent length per patient, mm 31.52 ± 19.11
Stent length per lesion, mm 22.65 ± 10.14
Lesion location (target vessel)
LAD, % (n) 40.16% (149)
LCX, % (n) 29.92% (111)
RCA, % (n) 28.57% (106)
LM, % (n) 1.08% (4)
Graft, % (n) 0.27% (1)
Number of vessels treated per patient, n 1.23 ± 0.47
Number of lesions treated per patient, n 1.41 ± 0.66
Vascular access site
Radial, % (n) 72.35% (191)
Femoral,% (n) 27.65% (73)
Complete revascularization 67.05% (177)
Preprocedural TIMI ﬂow grade
0–1, % (n) 13.59 % (48/353)
2, % (n) 18.13% (64/353)
3, % (n) 68.27% (241/353)
ACC/AHA lesion classiﬁcation
A, % (n) 4.24% (15/354)
B1, % (n) 15.54% (55/354)
B2, % (n) 50.00% (177/354)
C, % (n) 30.23% (107/354)
Thrombus present, % (n) 11.02% (39/354)
Calciﬁcation
None/mild, % (n) 87.57% (310/354)
Moderate, % (n) 8.76% (31/354)
Severe, % (n) 3.67% (13/354)
Ostial lesion, % (n) 5.08% (18/354)
Data are mean ± SD or %. LAD, left anterior descending; LCX, left circumﬂex; RCA, right corona
College of Cardiology/American Heart Association.2.5. Statistical analysis
The statistical analysis plan has previously been published [5]. The
CENTURY II randomized trial was powered for non-inferiority of BP-
SES compared with PP-EES for the primary endpoint of 9-month TLF.
The Kaplan–Meier method was used to estimate event rates for time-
to event outcomes, and data were compared with the log-rank test.
All analyses were carried out using the SAS software, version 9.1 (SAS
Institute, Inc., Cary, NC, USA).3. Results
3.1. Patient characteristics
Out of 1123 patients enrolled in CENTURY II, 264 were high risk ACS
patients whichwere randomly assigned to receive BP-SES (n= 126) or
PP-EES (n=138).Mean agewas 63.7 years, 82.2%weremale, and23.4%
were diabetic patients. In this subgroup, 23.1% were STEMI patients
while 76.9% were NSTEMI patients (Fig. 1). Baseline demographic and
clinical characteristics did not signiﬁcantly differ between two study
groups (Tables 1 and 2).3.2. Angiographic results
A total of 354 lesions (159 with BP-SES and 195 with PP-EES) were
treated with a mean of 1.7 stents implanted per patient. Treated vessel
was the left anterior descending (LAD) coronary artery in more than
40% of caseswith two thirds of theprocedures performed via transradial
approach. More than 75% of treated lesions displayed complex features
(B2 or C) as rated by the ACC/AHA. Details of procedural and lesions
characteristics are shown in Tables 2 and 3.BP-SES
N = 126
Nlesion = 166
PP-EES
N = 138
Nlesion = 205
P value
1.55 ± 0.77 1.75 ± 1.00 0.24
1.17 ± 0.44 1.19 ± 0.44 0.61
30.31 ± 17.50 32.62 ± 20.45 0.74
22.96 ± 10.49 22.39 ± 9.87 0.34
0.72
42.77% (71) 38.05% (78)
29.52% (49) 30.24% (62)
27.11% (45) 29.76% (61)
0.60% (1) 1.46% (3)
0.0% (0) 0.49% (1)
1.17 ± 0.39 1.28 ± 0.53 0.06
1.32 ± 0.59 1.49 ± 0.72 0.03
0.81
73.02% (92) 71.74% (99)
26.98% (34) 28.26% (39)
70.63% (89) 63.77% (88)
0.23
11.39% (18/158) 15.39% (30/195)
18.99% (30/158) 17.44% (34/195)
69.62% (110/158) 67.18% (131/195)
0.49
5.03% (8/159) 3.59% (7/195)
13.84% (22/159) 16.92% (33/195)
47.80% (76/159) 51.79% (101/195)
33.33% (53/159) 27.69% (54/195)
10.06% (16/159) 11.79% (23/195) 0.60
0.98
86.16% (137/159) 88.72% (173/195)
9.43% (15/159) 8.21% (16/195)
4.40% (7/159) 3.08% (6/195)
3.14% (5/159) 6.67% (13/195) 0.13
ry artery; LM, left main; TIMI, thrombolysis in myocardial infarction; ACC/AHA, American
able 4
linical outcomes at 24 months.
Total
HR-ACS
n = 264
BP-SES
n = 126
PP-EES
n = 138
P
value
All cause death, % (n) 2.2% (6) 1.5% (2) 2.9% (4) 0.48
Cardiac death, % (n) 1.1% (3) 0.0% (0) 2.1% (3) 0.10
All MI, % (n) 3.4% (9) 2.3% (3) 4.3% (6) 0.38
Target vessel MI, % (n) 2.2% (6) 0.7% (1) 3.6% (5) 0.12
All revascularizations, % (n) 10.2% (27) 8.7% (11) 11.5% (16) 0.44
Clinically indicated
revascularizations, % (n)
7.5% (20) 7.1% (9) 7.9% (11) 0.80
TLR, % (n) 4.5% (12) 5.5% (7) 3.6% (5) 0.45
TV non-TLR revascularization, % (n) 3.7% (10) 2.3% (3) 5.0% (7) 0.25
TVR, % (n) 6.4% (17) 5.5% (7) 7.2% (10) 0.58
NTVR, % (n) 5.6% (15) 5.5% (7) 5.8% (8) 0. 93
Composite endpoints
TLF, % (n) 6.4% (17) 6.3% (8) 6.5% (9) 0.95
TVF, % (n) 7.9% (21) 6.3% (8) 9.4% (13) 0.36
Cardiac death and MI, % (n) 4.1% (11) 2.3% (3) 5.8% (8) 0.17
All death, MI, and
revascularization, % (n)
13.2% (35) 11.9% (15) 14.5% (20) 0.54
LR, target lesion revascularization; TV, target vessel; TVR, target vessel revascularization;
TVR, non-target vessel revascularization; TLF, target lesion failure; TVF, target-vessel
ilure.
able 3
CA lesion characteristics.
Total HR-ACS
n = 264
BP-SES
n = 126
PP-EES
n = 138
P value
Number of lesions analyzed 354 159 195
Lesion length, mm 19.97 ± 10.07 21.04 ± 10.96 19.08 ± 9.20 0.14
Pre-procedure
RVD, mm 2.65 ± 0.59 2.68 ± 0.56 2.62 ± 0.62 0.29
MLD, mm 0.73 ± 0.42 0.75 ± 0.40 0.71 ± 0.44 0.52
% Diameter stenosis, % 72.29 ± 14.54 72.09 ± 13.36 72.45 ± 15.47 0.64
Post-procedure
MLD, mm
In-stent 2.51 ± 0.47 2.53 ± 0.46 2.49 ± 0.49 0.41
In-segment 2.14 ± 0.62 2.19 ± 0.60 2.11 ± 0.63 0.26
% Diameter stenosis, %
In-stent 12.46 ± 6.40 12.58 ± 6.30 12.37 ± 6.51 0.74
In-segment 23.90 ± 11.77 23.40 ± 11.68 24.31 ± 11.86 0.33
Acute gain, mm
In-stent 1.79 ± 0.54 1.78 ± 0.50 1.79 ± 0.56 0.91
In-segment 1.42 ± 0.65 1.44 ± 0.59 1.40 ± 0.69 0.42
ata are mean ± SD. QCA, quantitative coronary angiography; RVD, reference vessel di-
meter; MLD, minimal luminal diameter.
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Follow-up at 24 months was available in 98% (124/126 in BP-SES
group and 136/138 in PP-EES group) of the patients (Fig. 1). TLF oc-
curred in 6.3% (8/126) of patients receiving a BP-SES and 6.5% (9/138)
of patients receiving a PP-EES (P = 0.95) (Table 4). Individual compo-
nents of the TLF showed comparable rates of cardiac death (0.0% in
BP-SES and 2.1% in PP-EES; P = 0.10), target vessel MI (0.7% in BP-SES
and 3.6% in PP-EES; P = 0.12), and clinically driven TLR (4.8% BP-SES
and 3.6% PP-EES; P = 0.64) at 24-month follow-up. TVF occurred in
6.3% (8/126) of patients receiving a BP-SES and 9.4% (13/138) of pa-
tients receiving a PP-EES (P = 0.36) (Table 4). POCE at 24-month
post-stent implantation was 11.9% (15/126) of patients receiving a BP-
SES and 14.5% (20/138) of patients receiving a PP-EES (P = 0.58)
(Table 4). ST (deﬁnite + probable) occurred in 2 patients (1.59%) in
the BP-SES, and in one patient (0.72%) in the PP-EES group (P = 0.51),
all as subacute events (Table 5). At 12 and 24 months follow-up, 60%
and 19% of patients continued with DAPT, respectively, with no signiﬁ-
cant differences between groups. Since the polymer of the BP-SES
completely degrades over 3 to 4 months, we performed further land-
mark analysis to compare the clinical events occurring within the ﬁrst
4 months and beyond the ﬁrst 4months. Landmark Kaplan–Meier anal-
ysis for TLF, TVF, and POCEwithin 4months and up to 24months is pre-
sented in Figs. 2–4.
4. Discussion
This study reported the 24-month clinical outcomes of new-
generation BP-SES compared with PP-EES in ACS patients from the
CENTURY II trial. The Ultimaster BP-SES was similar to Xience PP-EES
with respect to TLF in patients with ACS, including STEMI and NSTEMI.
The good clinical performance and safety of Ultimaster BP-SES was par-
ticularly reﬂected in the low rates of cardiac death and MI achieved up
to 24 months, comparable with the PP-EES group, as well as in the
non-signiﬁcant differences obtained regarding POCE, with a similar fre-
quency of ST among BP-SES and PP-EES-treated patients, and without
any late event. The BP-SES matched the clinical outcomes of the PP-
EES, one of the safest and most effective DES currently available. This
is reassuring since PP-EES have previously been shown to improve out-
comes and reduce the risk ofmortality, MI, ST, and repeat revasculariza-
tion as compared to early-generation DES in challenging populations
including ACS patients [9,10].
4.1. Previous studies with BP-DES vs. PP-DES in ACS
Fewdata exist regarding the use of DESwith biodegradable polymer
in patients with ACS. In the subgroup of ACS patients of the COMPARE II
trial [11], the biodegradable polymer biolimus-eluting stent was non-
inferior to durable ﬂuoropolymer-based everolimus-eluting stent with
regards to the primary endpoint, a composite of safety (cardiac death
and non-fatal MI) and efﬁcacy (clinically indicated TVR) at 12 months
(5.2% in the biolimus-eluting stent group vs. 4.8% in the everolimus-
eluting stent group; Pnon-inferiority b 0.0001). Deﬁnite ST was similar in
both groups (0.7% vs. 0.4%, P = 0.38).
In the pooled individual patient-level analysis from three random-
ized clinical trials [12] (ISAR-TEST-3, ISAR-TEST-4 and LEADERS) com-
paring outcomes from BP-DES with PP-DES in 497 STEMI patients at
four years, the primary endpoint (comprised of cardiac death, MI, or
TLR), was signiﬁcantly reduced following treatment with BP-DES
(14.2% vs. 23%; P = 0.01) driven by reduced TLR (7.4% vs. 13.1%; P =
0.04). In addition, trends toward reduction for cardiac death or MI
(9.5% vs. 15.0%; P = 0.07) and deﬁnite or probable ST (3.6% vs. 7.1%;
P = 0.09) were reported in the BP-DES group.
In the prespeciﬁed subgroup of patients with STEMI of the
BIOSCIENCE (Ultrathin strut biodegradable polymer sirolimus-eluting
stent versus durable polymer everolimus-eluting stent for percutaneousT
Q
D
acoronary revascularization) trial [13], 407 (19%) STEMI patients were
included. Ultrathin strut biodegradable polymer stent was associated
with a lower risk of TLF (3.3%) than with durable polymer stent (8.7%;
P = 0.024) at 12 months.
These reports from subpopulation analysis are comparable with our
results, however prospective randomized clinical trials on a large scale
are needed, speciﬁcally those designed for this patient population.
4.2. Potential beneﬁt of BP-DES in ACS
ACS is constituted by a heterogeneous group of patients that differs
greatly from the population of patients with stable coronary disease,
showing a higher risk of developing subsequent coronary events such
as ST and reinfarction. Previous studies using intravascular imaging as-
sessment after DES implantation in STEMI patients have shown a higher
proportion of uncovered struts and incomplete stent apposition at
follow-up, potentially due to an adverse vessel remodeling and late-
acquired incomplete stent apposition, a phenomenon related to hyper-
sensitivity and attenuation of the vessel's healing processes induced by
DES polymer [14].T
C
T
N
fa
Table 5
Antiplatelet treatment, bleeding and stent thrombosis.
Total
HR-ACS
n = 264
BP-SES
n = 126
PP-EES
n = 138
P
value
Preprocedural antiplatelet
medications
Aspirin, % (n) 83.3% (220) 84.9% (107) 81.8% (113) 0.51
Clopidogrel, % (n) 46.5% (123) 48.4% (61) 44.9% (62) 0.57
Prasugrel, % (n) 10.9% (29) 9.5% (12) 12.3% (17) 0.47
Ticagrelor, % (n) 15.5% (41) 14.2% (18) 16.6% (23) 0.59
DAPT, % (n) 72.7% (192) 71.4% (90) 73.9% (102) 0.65
Stent thrombosis (deﬁnitive + probable) at 24-month,% (n)
Acute, % (n) 0.0% (0) 0.0% (0) 0.0% (0) 1.0
Subacute, % (n) 1.1% (3) 1.5% (2) 0.7% (1) 0.51
Late/very late, % (n) 0.0% (0) 0.0% (0) 0.0% (0) 1.0
DAPT use at 12 months, % (n) 60.0% (146) 62.0% (72) 58.2% (74) 0.55
DAPT use at 24 months, % (n) 19.2% (49) 21.3% (26) 17.4% (23) 0.43
Any bleeding 12 months, % (n) 9.4% (25) 8.7% (11) 10.1% (14) 0.56
Any bleeding 24 months, % (n) 11.7% (31) 11.9% (15) 11.5% (16) 0.93
DAPT, dual antiplatelet therapy.
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ity displayed by patientswithACS, and the delayed endothelialization of
PP-DES compared to BMS, favor the use of DAPT for long time, even in
populations with high concurrent bleeding risk. Therefore, the possibil-
ity of having a device that offers the advantages of DES in terms of re-
duction of repeat revascularizations and restenosis combined with the
safety of BMS regarding the risk of late thrombosis is highly attractive,
moreover adding the beneﬁt of current and more efﬁcient antiplatelet
therapies, could encouraged a possible reduction in DAPT duration in
ACS patients with high bleeding risk.
At present, there is no speciﬁc recommendation for DAPT duration
after BP-DES implantation. Consequently, it should not differ from
that of a PP-DES in current clinical practice until we have more data
from a larger patient population with longer term follow-up to conﬁrm
this theory.
The good performance obtained regarding safety and efﬁcacy by
the BP-SES in this study is encouraging and could be explained, in
part, by its bioresorbable polymer, abluminal coating, thinner cobalt-
chromium stent platform (80 μm) with an open-cell design for easy ac-
cess to a side branch and conformability to the vessel wall, the absence
of drug and polymer on blood contacting surface, and the short polymer
degradation time allow rapid drug elution (three to four months),Fig. 2. Landmark Kaplan–Meier analysis of target lesion failure (TLF) BP-SES = bioresorbable p
TLF = target lesion failure; HR = hazard ratio.which might promote early endothelialization. No signiﬁcant differ-
ences were observed during or beyond the 4-month polymer degrada-
tion period of Ultimaster BP-SES compared with Xience PP-EES,
regarding TLF, TVF, and POCE (Figs. 2–4). Also, previous studies have
demonstrated on OCT at 9-month follow-up the lower frequency of un-
covered struts with a BP-DES compared with a PP-DES [15].
Important factors implied in ST and restenosis such as localized hy-
persensitivity reaction to the polymer or its carriers causing delayed
healing, and stent coverage by non-functional endothelium are avoided
by the use of a BP [14]. In the CENTURY study, the Ultimaster BP-SES
showed almost complete stent endothelialization after 6 months of im-
plantation, with absence of vessel remodeling and unchanged vessel
volume peri-stent by IVUS and OCT analysis [16].
Whether the degree of strut coverage and lack of malapposition
(evaluated by OCT) are sufﬁcient parameters to safely discontinue
DAPT without the risk of ST is currently not known and needs to be
properly assessed in a prospective clinical trial. It also remains to be
demonstrated whether the use of new technologies as BP with thin-
strut stent platforms, seeking to achieve a more rapid re-
endothelialization and an improved healing pattern, will overcome
the small drawbacks of current DES-generation in terms of ST and
stent restenosis. Moreover, these beneﬁts should be compared with a
variety of new DES technologies with ultrathin platform, DES without
polymer, and the bioresorbable scaffolds in ACS patients.
4.3. Limitations
This is a pre-speciﬁed subgroup analysis of a large randomized, pro-
spective, multicenter study. The CENTURY II study reached its primary
endpoint by showing non-inferiority of TLF at 9 months in patients
treated with BP-SES comparing with patients treated with PP-EES, but
was not powered to address individual components of efﬁcacy or safety.
This sample size of this ACS subgroup is small and events rates were
low, therefore does not have sufﬁcient power to draw deﬁnite conclu-
sions from this subgroup analysis. Our ﬁndings should be considered
only as hypothesis-generating. The study patients were enrolled from
high-volume centers in 11 European countries. Therefore, geographical
variations in PCI practice outside Europe or in lower-volume centers
cannot be excluded. CENTURY II had limited exclusion criteria (Appen-
dix), and this subgroup included ACS patients with complex anatomical
disease. However, that might not fully represent the real features of the
population treated in our routine clinical practice.olymer sirolimus-eluting stent; PP-EES = permanent polymer everolimus-eluting stent;
Fig. 3. Landmark Kaplan–Meier analysis of target vessel failure (TVF) BP-SES = bioresorbable polymer sirolimus-eluting stent; PP-EES = permanent polymer everolimus-eluting stent;
TVF = target vessel failure; HR= hazard ratio.
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Our ﬁndings suggest that the use of Ultimaster BP-SES in patients
with high risk ACS, including STEMI, is non-inferior to the Xience PP-
EES regarding composite clinical endpoints of cardiac death, TV-MI or
TLR at 24 months and is associated with a favorable safety proﬁle as ev-
idenced by similar rates of ST throughout 2 years. The latter ﬁnding is
hypothesis-generating and requires validation in appropriately de-
signed studies.
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